Answers are grounded in this paper and cite their sources.
Objective CFTR modulator therapy has changed the landscape of Cystic Fibrosis care with reports of improved quality of life and physiological markers for adults and adolescents with Cystic Fibrosis (CF), however little is known about the lived experience of caregivers. This study explored parents’ experiences of initiating elexacaftor/tezacaftor/ivacaftor (ETI) in young children with CF in the United Kingdom. Method Three focus groups facilitated by a topic guide were conducted with parents via Microsoft Teams. The focus groups were recorded and transcribed, and thematic analysis was used to identify the main themes. Results Thirteen participants (10 mothers and three fathers) participated. Four main themes were identified: (1) Navigating the hurdles; The feeling of parental responsibility when starting a new medication (2) “It's just one giant guessing game: Is it the medication, or is it my child?” (3) “It is a payoff” benefit observed outweighing the potential side effects for parents (4) Beyond the clinical trials; the practicalities of caring for a young child on ETI. Discussion Starting a new medication is a considered, balanced decision for families, with significant parental responsibility felt emotionally and practically. Clinical teams must work collaboratively with families to support decision-making and monitor young children while introducing new therapies.
No takes yet. Share an insight, caveat, or question.
Davies et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: